Click on headlines below to download research

SEL120 to enter clinical development in 2019
Selvita | 18/01/2019

The data readout from the SEL24 Phase I/II trial in relapsed/refractory AML and the second lead asset, SEL120, moving into clinical development next year…

Progress across pipeline; Services sales up 53%
Selvita | 29/06/2018

Over the past several months Selvita has been executing on its new R&D-focused multi-year strategy funded by the share issue in March 2018 raising…

New funds enable expanded R&D programme
Selvita | 16/04/2018

Selvita’s FY17 revenues were PLN105.9m, up 59% y-o-y, with adjusted operating profit rising from PLN4.7m to PLN13.2m. This reflects strong organic…